Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.64 |
| ▸ | CA2 | P00918 | 8/20 | 0.64 |
| ▸ | CA9 | Q16790 | 8/20 | 0.64 |
| ▸ | CA12 | O43570 | 3/20 | 0.64 |
| ▸ | CA3 | P07451 | 1/20 | 0.64 |
| ▸ | CA4 | P22748 | 1/20 | 0.64 |
| ▸ | CA6 | P23280 | 1/20 | 0.64 |
| ▸ | CA5A | P35218 | 1/20 | 0.64 |
| ▸ | CA7 | P43166 | 1/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.64 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.54 |
| ▸ | IL1RN | P18510 | 1/20 | 0.54 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.54 |
| ▸ | LPL | P06858 | 1/20 | 0.53 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20995717 | 0.94 | CA9 (0.62) | CA1CA2CA9CA12CA3 | |
| SCHEMBL4909467 | 0.87 | CA1 (0.65) | CA1CA2CA9CA12CA3 | |
| SCHEMBL18395483 | 0.86 | CA1 (0.63) | CA1CA2CA9CA12CA3 | |
| SCHEMBL15504644 | 0.86 | CA1 (0.63) | CA1CA2CA9CA12CA3 | |
| SCHEMBL11894843 | 0.85 | HTR6 (0.51) | CA1CA2CA9CA12CA3 | |
| SCHEMBL5674321 | 0.83 | CA1 (0.61) | CA1CA2CA9CA12CA3 | |
| SCHEMBL3262774 | 0.82 | CA1 (0.60) | CA1CA2CA9CA12CA3 | |
| SCHEMBL790984 | 0.81 | ALPL (0.48) | CA1CA2CA9CA12CA3 | |
| SCHEMBL15091914 | 0.81 | CA1 (0.58) | CA1CA2CA9CA12CA3 | |
| SCHEMBL31438923 | 0.81 | CA1 (0.58) | CA1CA2CA9CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119725741-A | Electrolyte for lithium iron manganese phosphate system battery and lithium ion battery | 安徽得壹能源科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-2569301-A1 | INDAZOLE INHIBITORS OF KINASE | Abbvie Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-8293738-B2 | Indazole inhibitors of kinase | ABBOTT LABORATORIES (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2487175-A1 | PHARMACEUTICAL PRODUCT CONTAINING AROMATIC HETEROCYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196854-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AROMATIC HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20110281868-A1 | INDAZOLE INHIBITORS OF KINASE | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2011143430-A1 | INDAZOLE INHIBITORS OF KINASE | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | WO | disclosed |
| US-8003655-B2 | Dysregulated vascular growth diseases; tyrosine kinase with immunoglobulin and epidermal growth factor homology domain inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003655-B2 | Dysregulated vascular growth diseases; tyrosine kinase with immunoglobulin and epidermal growth factor homology domain inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003655-B2 | Dysregulated vascular growth diseases; tyrosine kinase with immunoglobulin and epidermal growth factor homology domain inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| EP-2046758-A1 | SUBSTITUTED SULPHOXIMINES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-15 | — | — | EP | disclosed |
| US-7494995-B2 | Phenylpyridylpiperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-02-24 | — | — | US | disclosed |
| US-20080064696-A1 | SUBSTITUTED SULPHOXIMINES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064696-A1 | SUBSTITUTED SULPHOXIMINES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064696-A1 | SUBSTITUTED SULPHOXIMINES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-13 | — | — | US | disclosed |
| WO-2008006560-A1 | SUBSTITUTED SULPHOXIMINES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-01-17 | — | — | WO | disclosed |
| EP-1878726-A1 | Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-16 | — | — | EP | disclosed |
| US-20060258671-A1 | Phenylpyridylpiperazine compounds | LES LABORATORIES SERVIER (FR) | 2006-11-16 | — | — | US | disclosed |
| EP-1721896-A1 | Phenylpyridinylpiperazin derivatives, the process to make them and the compositions containing them | Les Laboratoires Servier (FR) | 2006-11-15 | — | — | EP | disclosed |
| US-20060194823-A1 | Sulfonamido-macrocycles as Tie2 inhibitors and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194823-A1 | Sulfonamido-macrocycles as Tie2 inhibitors and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof | TEK, TIE1, KDR | CA1 3872/4885CA2 1503/4885CA9 2323/4885 |
| US-20060258671-A1 | Phenylpyridylpiperazine compounds | HRH4, HRH3, HRH2 | CA1 3410/4885CA2 2295/4885CA9 4510/4885 |
| US-20110281868-A1 | INDAZOLE INHIBITORS OF KINASE | AURKA, AURKC, AURKB | CA1 3477/4885CA2 1064/4885CA9 2444/4885 |
| US-20120196854-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AROMATIC HETEROCYCLIC COMPOUND | CYP2C18, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2B6 | CA1 3327/4885CA2 2053/4885CA9 2295/4885 |
| US-20080064696-A1 | SUBSTITUTED SULPHOXIMINES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | TIE1, KDR, TEK | CA1 4147/4885CA2 1369/4885CA9 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.